# Systolic pulmonary regurgitation affects the outcome of patients with severe systolic heart failure

Shih-Hung Hsiao<sup>1</sup>, Chao-Sheng Hsiao<sup>1,2</sup> and Kuan-Rau Chiou<sup>3,4\*</sup>

<sup>1</sup>Division of Cardiology, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan; <sup>2</sup>Department of Internal Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; <sup>3</sup>Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, No. 291, Jhongzheng Road, Jhonghe District, New Taipei City, 23561, Taiwan; and <sup>4</sup>School of Medicine, Taipei Medical University, Taipei, Taiwan

# Abstract

**Aims** Little is known of the impact of systolic pulmonary regurgitation (PR) on acute decompensated heart failure (HF). We assessed the prevalence and prognostic significance of systolic PR in patients with severe HF.

**Methods and results** According to recent 10 year echocardiographic database of E-Da Hospital, 533 patients admitted for first systolic heart failure (HF) and left ventricular ejection fraction <35% were under investigation. Systolic PR was defined as the presence of pulmonary backward flow persistent after QRS in electrocardiogram. Isovolumic contraction/relaxation time and myocardial performance index were derived by tissue Doppler imaging. Right ventricular (RV) function was assessed by RV fractional area change. Estimated pulmonary vascular resistance (PVR) was assessed by the ratio of peak tricuspid regurgitation velocity to the RV outflow tract time–velocity integral. The factors associated with systolic PR were assessed by multivariate logistic regression. Cox proportional regression analyses were used to estimate the impact of cardiovascular events including HF rehospitalization and cardiovascular death. For estimated prevalence of 5480 control subjects, echocardiographic screens in those with normal left ventricular ejection fraction were performed. Of 533 systolic HF cases, 143 (26.8%) had systolic PR during indexed hospitalization. Among 143 cases, 86% systolic PR disappeared during late follow-up. In control subjects, 0.3% (18/5480) had systolic PR. Systolic PR correlated to RV dysfunction, estimated PVR, E/e/, sign of low cardiac output, and pulmonary oedema. Systolic PR was associated independently with further cardiovascular events (hazard ratio 2.266, 95% confidence interval 1.682–3.089, P < 0.0001) including cardiovascular death and HF rehospitalization.

**Conclusions** Systolic PR is not uncommon in systolic HF and is associated with high PVR and RV dysfunction. Systolic PR significantly impacts cardiovascular outcome.

Keywords Systolic pulmonary regurgitation; Heart failure; Pulmonary vascular resistance; Prognosis

Received: 12 June 2021; Revised: 22 July 2021; Accepted: 10 August 2021

\*Correspondence to: Kuan-Rau Chiou, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, No. 291, Jhongzheng Road, Jhonghe District, New Taipei City 23561, Taiwan. Tel: 886-2-22490088x8152; Fax: 886-2-28731013. Email: krchiou@hotmail.com

# Introduction

Pulmonary regurgitation (PR) is defined as an abnormal reversal of blood flow from the pulmonary artery into the right ventricle. PR is early diastolic phase, most commonly seen secondary to various aetiologies causing pulmonary hypertension and dilation of the pulmonary artery. PR has a similar haemodynamic basis as aortic regurgitation (AR) except that the changes in pressures and volumes are noted on the right side of the heart (pulmonary artery, right ventricle, and right atrium).

Systolic AR had been identified in valvular heart disease or heart failure (HF) and showed capability for predicting HF.<sup>1–6</sup> Systolic AR was explained as the inability of the ventricular contraction to overcome the aortic pressure in patients with valvular incompetence. This phenomenon is associated with pulsus alternans and ineffective contraction, which is common in severe left-side HF.<sup>7</sup>

We found that simultaneous tricuspid regurgitation and PR at systolic phase in patients with acute decompensated HF (*Figure 1A–1D*), and systolic PR disappeared after discharge. The prevalence and clinical significance of systolic PR were

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

**Figure 1** Simultaneous tricuspid regurgitation and pulmonary regurgitation (PR) at systolic phase in patients with acute decompensated heart failure. (A) Systolic PR simultaneous with tricuspid regurgitation at a patient with acute heart failure due to post-partum cardiomyopathy and (B) continuous-wave Doppler recording over right ventricular outflow tract; (C) the same phenomenon occurred at a patient with acute ischaemic heart failure and (D) continuous-wave Doppler over right ventricular outflow tract.



not investigated before. After searching for systolic PR and HF in MEDLINE, only one article mentioned end-diastolic PR pressure gap, which was associated with left ventricular (LV) filling pressure, showing prognostic significance in HF cases.<sup>8</sup> In line with systolic AR presenting in systolic LV HF, we hypothesized that systolic PR could be a phenomenon of biventricular HF if right ventricular (RV) dysfunction cannot overcome elevated pulmonary vascular resistance (PVR). Accordingly, the study was retrospectively conducted to assess the frequency and outcome impact of systolic PR, and invasive haemodynamic study in cases with acute decompensated HF.

# Methods

## **Patient enrolment**

Retrospective screening of E-Da Hospital 10 year database of hospitalization for acute severe systolic LV HF was performed

to clarify the true prevalence of systolic PR in this cohort. Severe LV systolic dysfunction is defined as LV ejection fraction (LVEF) <35%. The echocardiograms at first admission of systolic LV HF were reviewed, and all patients were subdivided according to the presence of systolic PR. We also screened echocardiographic database of past 1 year to detect the systolic PR prevalence in cohort with normal LVEF. The study protocol was approved by the institutional review board of E-Da Hospital. The requirement for written informed consent was waived by clinic institutional review board that gave its approval for this study.

## **Clinical characteristics**

History of diabetes, hypertension, and smoking was recorded. At the index HF admission, subjects were considered hypertensive if they had high blood pressure or were under hypertension drug treatment. Diabetes mellitus was defined according to American Diabetes Association criteria.<sup>9</sup> At enrolment, creatinine clearance (CCr) was estimated by Cockcroft-Gault equation, and renal dysfunction was defined as CCr  $< 60 \text{ mL/min}/1.73 \text{ m}^{2.10}$  All electrocardiograms (ECGs) were reviewed for atrial fibrillation and bundle branch block. Coronary artery disease was defined as any history of the following: (i) myocardial infarction; (ii) at least 70% stenosis in one or more coronary vessels on coronary angiography; (iii) exercise-induced ischaemia indicated by treadmill electrocardiogram, nuclear perfusion stress imaging, or coronary computed tomography angiogram; or (iv) coronary revascularization. Any signs of HF at index HF hospitalization were under detailed reviews. Pulmonary oedema is defined as paroxysmal nocturnal dyspnoea, orthopnoea, pulmonary rales, a third heart sound, and pulmonary oedema on chest radiography, and low cardiac output is defined as inadequate peripheral perfusion including cold limbs, postural hypotension, effort-related tachycardia, oliguria, and poor digestion.

#### **Echocardiographic parameters**

Left ventricular ejection fraction was calculated by Simpson biplane technique. RV fractional area change was assessed by RV area change between systolic and diastolic phases at apical four-chamber views. RV dysfunction was defined as RV fractional area change <35%. Pulmonary artery systolic pressure was estimated using Doppler echocardiography by calculating RV to right atrial pressure gradient during systole. Right atrial pressure, estimated on the basis of echocardiographic characteristics of the inferior vena cava,<sup>11</sup> was then added to the calculated gradient. Pulsed-wave tissue Doppler imaging (TDI) was performed in apical views, and a pulsed-wave Doppler sample volume was placed at the level of the mitral annulus over the septal, lateral borders and RV basal annulus. The average early diastolic velocity (e/) of the septal and lateral mitral annuli was used in E/e/ for assessing diastolic filling.<sup>12</sup> Myocardial performance index of the right ventricle was calculated according to isovolumic contraction time (IVCT), relaxation time, and ejection time derived from TDI over RV basal annulus.<sup>13</sup> PVR was assessed by the ratio of peak tricuspid regurgitation velocity (TRV, m/s) to the RV outflow tract time-velocity integral (TVI<sub>RVOT</sub>, cm) obtained by Doppler echocardiography (TRV/TVI<sub>RVOT</sub>  $\times$  10 + 0.16; Wood units, multiply 80 dyn·s/cm<sup>5</sup>).<sup>14–16</sup>

## Definition of systolic pulmonary regurgitation and severity

Pulmonary regurgitation was assessed according to PR jet flow echo density compared with forward flow, PR jet deceleration time at continuous-wave Doppler measurement over RV outflow tract of parasternal short-axis view, and PR vena contracta/pulmonary artery diameter. If PR jet flow was

5123

<260 ms, and PR vena contracta/pulmonary artery diameter was >0.7, it indicated severe PR. If PR jet flow density was soft, and PR vena contracta/pulmonary artery diameter was <0.5, it indicated mild tricuspid regurgitation. The other was defined as moderate PR.<sup>17</sup> Systolic PR was defined as the duration of PR beyond the QRS of ECG tracing, based on the presence of backward flow over pulmonary valve beyond QRS at colour Doppler image in parasternal short-axis view. Because systolic PR flow density and the ratio of vena contracta were less than PR, the grade of systolic PR was based on the diameter of vena contracta in the current study. If vena contracta of systolic PR was >0.7 cm, it was defined as Grade 3. If vena contracta of systolic PR was <0.5 cm, it was classified as Grade 1. The other was defined as Grade 2. The duration of systolic PR was measured as the interval from the initiation of QRS to the termination of systolic PR. The maximal velocities of PR and systolic PR were measured by continuous-wave Doppler at parasternal short-axis view.

#### **Outcome assessment**

The endpoints were HF rehospitalization and cardiovascular death after first HF admission. Hospitalization for HF was defined as a hospital stay of at least one night for treatment of a clinical syndrome with at least two of the following symptoms: low cardiac output, paroxysmal nocturnal dyspnoea, orthopnoea, elevated jugular venous pressure, pulmonary rales, a third heart sound, cardiomegaly on chest radiography, or pulmonary oedema on chest radiography. These clinical signs and symptoms might have represented a clear change from the normal clinical state of the patient and might have been accompanied by either failing cardiac output, as determined by peripheral hypoperfusion, or peripheral or pulmonary oedema requiring treatment with vasodilators, inotropes, or intravenous diuretics. Supportive documentation of a decreased cardiac index, an increased pulmonary capillary wedge pressure, decreasing oxygen saturation, and end-organ hypoperfusion, if available, was included in the adjudication. The definition of events was based on medical record reviews. For those with loss of follow-up or possible mortality, medical assistants telephoned patients or family to assess any cardiovascular event through medical interview. The certification of cardiovascular death was based on death records, death certificates, and hospital medical records.

#### Statistical analysis

The SPSS software (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Baseline characteristics and echocardiographic parameters were analysed according to the presence of systolic PR or not. All continuous variables were presented as means ± standard deviation. A *P* value <0.05 was considered statistically significant. Clinical characteristics were compared by  $\chi^2$  analysis of categorical variables. Kaplan–Meier curves of cardiovascular events according to systolic PR were estimated by the log-rank test. The relationship between the presence of systolic PR and clinical

characteristics was assessed by multivariate logistic regression analyses. Cox proportional hazards regression models were used to analyse outcomes according to time-to-event data and associations between cardiovascular events and systolic PR while controlling for baseline characteristics and echocardiographic parameters.

Variables         N = 390         N = 143         P values           Age (years) $64 \pm 15$ $65 \pm 16$ $0.435$ Systolic BP (mmHg) $104 \pm 28$ $108 \pm 31$ $0.116$ Heart rate (hp,m.) $95 \pm 15$ $97 \pm 17$ $0.114$ Male gender (%) $123 (33.8%)$ $52 (36.4%)$ $0.023$ Typertension (%) $127 (33.8%)$ $52 (35.4%)$ $0.024$ Coronary artery disease (%) $201 (51.5%)$ $69 (48.3\%)$ $0.476$ Atrial fibrillation (%) $32 (21\%)$ $23 (3.8\%)$ $0.476$ March Lobick (%) $82 (21\%)$ $23 (16.1\%)$ $0.032$ Reard Aysfunction (%) $82 (21\%)$ $23 (16.1\%)$ $0.432$ Heart failure NHA FC (1-4) at enrolment $2.9 \pm 0.8$ $0.945$ $0.045$ Aptic regurgitation grade (0-3) $1.7 \pm 0.8$ $2.2 \pm 0.8$ $0.0001$ Aptic regurgitation grade (0-3) $1.5 \pm 0.6$ $0.7 \pm 0.8$ $0.001$ Aptic regurgitation grade (0-3) $1.5 \pm 0.6$ $0.7 \pm 0.8$ $0.0001$ Notic stenosis more than moderate degree (%) <th></th> <th>No systolic PR</th> <th>Systolic PR</th> <th></th>		No systolic PR	Systolic PR	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Variables	N = 390	<i>N</i> = 143	P values
Systolic BP (mmHg)         104 ± 28         108 ± 31         0.116           Heart rate (b,p,m)         95 ± 15         97 ± 17         0.141           Male gender (%)         171 (33.8%)         74 (51.7%)         0.025           Diabetes (%)         126 (32.3%)         36 (25.2%)         0.044           Coronary artery disease (%)         201 (51.5%)         66 (48.3%)         0.476           Atrial fibrillation (%)         136 (34.9%)         53 (38.5%)         0.032           Bundle branch block (%)         82 (21%)         23 (16.1%)         0.032           Reard dysfunction (%)         116 (29.7%)         45 (31.5%)         0.0476           Mitral stensois more than moderate degree (%)         17 ± 0.8         2.2 ± 0.8         <00001	Age (years)	64 ± 15	65 ± 16	0.435
Heart rate (b, p.m.) $95 \pm 15$ $97 \pm 17$ 0.141 Male gender (%) 132 (33.8%) 52 (36.4%) 0.273 Hypertension (%) 171 (33.8%) 74 (51.7%) 0.025 Diabetes (%) 26 (32.3%) 36 (25.2%) 0.044 Coronary artery disease (%) 201 (51.5%) 69 (48.3%) 0.476 Atrial fibrillation (%) 136 (34.9%) 55 (38.5%) 0.19 Bundle branch block (%) 82 (21%) 23 (16.1%) 0.082 Renal dysfunction (%) 116 (29.7%) 24 (51.5%) 0.432 Hart failure NTMA FC (1-4) at enrolment 2.9 $\pm 0.8$ 2.9 $\pm 0.8$ 0.99 $\pm 0.8$ 0.896 Mitral stenosis more than moderate degree (%) 15 (3.8%) 10 (7%) 0.082 Aortic stenosis more than moderate degree (%) 10 (2.6%) 5 (3.5%) 0.632 Aortic regurgitation grade (0-3) 0.6 $\pm 0.6$ 0.7 $\pm 0.8$ 0.091 Tricuspid regurgitation grade (0-3) 1.5 $\pm 0.6$ 1.9 $\pm 0.6$ 0.70 $\pm 0.8$ 0.0001 Aortic stenosis more than moderate degree (%) 10 (2.6%) 3 (2.1%) 0.261 Prosthetic antiral valve 8 (2.1%) 3 (2.1%) 0.261 Prosthetic antiral valve 8 (2.1%) 3 (2.1%) 0.271 Prosthetic antiral valve 7 (1.8%) 3 (2.1%) 0.271 PASP (mmHg) 44 $\pm 14$ 12 $\pm 1 \pm 14$ <0.0001 VV end-systolic volume (mL) 124 $\pm 34$ 128 $\pm 39$ 0.283 UVEF (%) 29 $\pm 5$ 28 $\pm 5$ 0.722 Fier (%) 20 $\pm 9 \pm 5$ 28 $\pm 5$ 0.722 Fier (%) 20 $\pm 9 \pm 5$ 28 $\pm 5$ 0.723 Fireury (100) 78 $\pm 16$ 106 $\pm 21$ <0.0001 NV IVT (ms) 78 $\pm 16$ 106 $\pm 21$ <0.0001 Estimated PVR (dyn sym <sup>2</sup> ) 3.0 $\pm 0.5$ 3.3 $\pm 0.5$ 0.344 Output for the failure 9 Pulmonary cedema (%) 296 (75.6%) 131 (91.6%) 0.001 Low cardia performance index 0.73 $\pm 0.26$ 0.73 $\pm 0.26$ 0.0021 Firme-velocity (ms) 26 (475.8%) 121 (84.6%) <0.0001 Low cardia couput (%) 26 (475.8%) 131 (91.6%) 0.0001 Low cardia couput (%) 26 (475.6%) 131 (91.6%) 0.0001 Low cardia couput (%) 26 (475.8%) 131 (91.6%) 0.0001 Low cardia couput (%) 26 (475.6%) 131 (91.6%) 0.0001 Low cardia couput (%) 26	Systolic BP (mmHg)	$104 \pm 28$	108 ± 31	0.116
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Heart rate (b.p.m.)	95 ± 15	97 ± 17	0.141
Hypertension (%)         171 (33.8%)         74 (51.7%)         0.025           Diabetes (%)         126 (32.3%)         36 (25.2%)         0.044           Coronary artery disease (%)         201 (51.5%)         69 (48.3%)         0.476           Atrial fibrillation (%)         136 (34.9%)         55 (38.5%)         0.19           Bundle branch block (%)         82 (21%)         23 (16.1%)         0.082           Renal dysfunction (%)         116 (29.7%)         45 (31.5%)         0.432           Mitral stenosis more than moderate degree (%)         15 (3.8%)         10 (7%)         0.083           Aortic stenosis more than moderate degree (%)         10 (2.6%)         5 (3.5%)         0.362           Aortic stenosis more than moderate degree (%)         10 (2.6%)         5 (3.5%)         0.362           Aortic stenosis more than moderate degree (%)         10 (2.6%)         3 (2.1%)         0.874           Prosthetic antral valve         7 (1.8%)         3 (2.1%)         0.874           Prosthetic antral valve         7 (1.8%)         3 (2.1%)         0.261           PASP (mmHig)         44 ± 14         51 ± 14         <0.0001	Male gender (%)	132 (33.8%)	52 (36.4%)	0.273
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Hypertension (%)	171 (33.8%)	74 (51.7%)	0.025
Coronary artery disease (%)         201 (51.5%)         69 (48.3%)         0.476           Atrial fibrillation (%)         136 (34.9%)         25 (38.5%)         0.19           Bundle branch block (%)         82 (21%)         23 (16.1%)         0.082           Renal dysfunction (%)         116 (29.7%)         45 (31.5%)         0.432           Mitral stenosis more than moderate degree (%)         15 (3.8%)         10 (7%)         0.083           Mitral stenosis more than moderate degree (%)         10 (2.6%)         5 (3.5%)         0.362           Aortic stenosis more than moderate degree (%)         10 (2.6%)         5 (3.5%)         0.362           Aortic regurgitation grade (0-3)         1.5 ± 0.6         0.7 ± 0.8         0.21%)         0.864           Posthetic mitral valve         7 (1.8%)         3 (2.1%)         0.821         0.84           Posthetic acritic valve         7 (1.8%)         3 (2.1%)         0.261         0.8001           Very fractional area change (%)         44 ± 9         30 ± 10         <0.0001	Diabetes (%)	126 (32.3%)	36 (25.2%)	0.044
Atrial fibrillation (%)       136 (34.9%)       55 (38.5%)       0.19         Bundle branch block (%)       82 (21%)       23 (16.1%)       0.082         Renal dysfunction (%)       116 (29.7%)       45 (31.5%)       0.432         Heart failure NYHA FC (1-4) at enrolment       2.9 ± 0.8       2.9 ± 0.8       0.896         Mitral stensis more than moderate degree (%)       15 (3.8%)       10 (7%)       0.083         Aortic regurgitation grade (0-3)       1.7 ± 0.8       2.2 ± 0.8       <00001	Coronary artery disease (%)	201 (51.5%)	69 (48.3%)	0.476
Bundle branch block (%)       82 (21%)       23 (16.1%)       0.082         Renal dysfunction (%)       116 (29.7%)       45 (31.5%)       0.432         Heart failure NYHA FC (1-4) at enrolment       2.9 ± 0.8       2.9 ± 0.8       0.896         Mitral stenosis more than moderate degree (%)       15 (3.8%)       10 (7%)       0.083         Aortic regurgitation grade (0-3)       1.7 ± 0.8       2.2 ± 0.8       0.0001         Aortic regurgitation grade (0-3)       0.6 ± 0.6       0.7 ± 0.8       0.091         Tricuspid regurgitation grade (0-3)       1.5 ± 0.6       1.9 ± 0.6       <0.0001	Atrial fibrillation (%)	136 (34.9%)	55 (38.5%)	0.19
Renal dysfunction (%)       116 (29,7%)       45 (31.5%)       0.432         Heart failure NYHA FC (1-4) at enrolment       2.9 ± 0.8       2.9 ± 0.8       0.896         Mitral stenosis more than moderate degree (%)       15 (3.8%)       10 (7%)       0.083         Mitral regurgitation grade (0-3)       1.7 ± 0.8       2.2 ± 0.8       <00001	Bundle branch block (%)	82 (21%)	23 (16.1%)	0.082
Heart failure NYHA FC (1-4) at enrolment $2.9 \pm 0.8$ $2.9 \pm 0.8$ $0.896$ Mitral stenosis more than moderate degree (%) $15 (3.8\%)$ $10 (7\%)$ $0.083$ Mitral regurgitation grade (0-3) $1.7 \pm 0.8$ $2.2 \pm 0.8$ $<00001$ Aortic stenosis more than moderate degree (%) $10 (2.6\%)$ $5 (3.5\%)$ $0.362$ Aortic regurgitation grade (0-3) $0.6 \pm 0.6$ $0.7 \pm 0.8$ $0.091$ Tricuspid regurgitation grade (0-3) $1.5 \pm 0.6$ $1.9 \pm 0.6$ $<0.001$ Prosthetic mitral valve $7 (1.8\%)$ $3 (2.1\%)$ $0.874$ Prosthetic aortic valve $7 (1.8\%)$ $3 (2.1\%)$ $0.261$ PASP (mmHg) $44 \pm 14$ $51 \pm 14$ $<0.0001$ LV end-diastolic volume (mL) $104 \pm 26$ $103 \pm 32$ $0.443$ LVEF (%) $29 \pm 5$ $28 \pm 5$ $0.722$ LVef (vs) $29 \pm 5$ $28 \pm 5$ $0.722$ LVer (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV IVRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV My (crims) $73 \pm 0.26$ $0.77 \pm 0.28$ $<0.0001$ RV MRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV My (dyn: $\sqrt{m^5})$ $172 \pm 32$ $238 \pm 54$ $<0.0001$ Itimated PWR (dyn: $\sqrt{m^5})$ $121 (84.6\%)$ $<0.0001$ RV My (dyn) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ Low cardiac output (%)	Renal dysfunction (%)	116 (29.7%)	45 (31.5%)	0.432
Mitral stenosis more than moderate degree (%)15 (3.8%)10 (7%)0.083Mitral regurgitation grade (0-3)1.7 $\pm$ 0.82.2 $\pm$ 0.8<00001	Heart failure NYHA FC (1–4) at enrolment	$2.9 \pm 0.8$	$2.9 \pm 0.8$	0.896
Mitral regurgitation grade $(0-3)$ 1.7 ± 0.82.2 ± 0.8<00001Aortic regurgitation grade $(0-3)$ 10 (2.6%)5 (3.5%)0.362Aortic regurgitation grade $(0-3)$ 0.6 ± 0.60.7 ± 0.80.091Tricuspid regurgitation grade $(0-3)$ 1.5 ± 0.61.9 ± 0.6<0.001	Mitral stenosis more than moderate degree (%)	15 (3.8%)	10 (7%)	0.083
Aortic stenosis more than moderate degree (%)10 (2.6%)5 (3.5%)0.362Aortic regurgitation grade (0-3)0.6 $\pm$ 0.60.7 $\pm$ 0.80.091Tricuspid regurgitation grade (0-3)1.5 $\pm$ 0.6-0.0001Prosthetic artic valve8 (2.1%)3 (2.1%)0.874Prosthetic artic valve7 (1.8%)3 (2.1%)0.2611PASP (mmHg)44 $\pm$ 1451 $\pm$ 14<0.0001	Mitral regurgitation grade (0–3)	$1.7 \pm 0.8$	$2.2 \pm 0.8$	<00001
Aortic regurgitation grade (0-3) $0.6 \pm 0.6$ $0.7 \pm 0.8$ $0.091$ Tricuspid regurgitation grade (0-3) $1.5 \pm 0.6$ $1.9 \pm 0.6$ $<0.0001$ Prosthetic mitral valve $8 (2.1\%)$ $3 (2.1\%)$ $0.874$ Prosthetic aortic valve $7 (1.8\%)$ $3 (2.1\%)$ $0.874$ Prosthetic aortic valve $7 (1.8\%)$ $3 (2.1\%)$ $0.874$ PASP (mmHg) $44 \pm 14$ $51 \pm 14$ $<0.0001$ RV fractional area change (%) $44 \pm 9$ $30 \pm 10$ $<0.0001$ LV end-systolic volume (mL) $124 \pm 34$ $128 \pm 39$ $0.283$ LV end-systolic volume (mL) $101 \pm 26$ $103 \pm 32$ $0.443$ LVEF (%) $29 \pm 5$ $28 \pm 5$ $0.722$ E/er $20.5 \pm 9.7$ $24.4 \pm 9.5$ $0.004$ RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV IMR (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV mocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.322$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn s/cm <sup>5</sup> ) $122 (467.8\%)$ $121 (94.6\%)$ $<0.0001$ RV failure (%) $244 (67.8\%)$ $121 (94.6\%)$ $<0.0001$ Pulmonary actery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $<0.0001$ RV iainer (%) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $<0.0001$ Pulmonary regurgitation severity (0-3) $17.9 \pm 56$ $219 \pm 58$ $<0.0$	Aortic stenosis more than moderate degree (%)	10 (2.6%)	5 (3.5%)	0.362
Tricuspid regurgitation grade (0-3)1.51.51.90.6<0.0001Prosthetic antiral valve8 (2.1%)3 (2.1%)0.261PASP (mmHg)44145114<0.0001	Aortic regurgitation grade (0–3)	$0.6 \pm 0.6$	$0.7 \pm 0.8$	0.091
Prosthetic mitral valve8 (2.1%)3 (2.1%)0.874Prosthetic aortic valve7 (1.8%)3 (2.1%)0.261PASP (mmHg)44 ± 1451 ± 14<0.0001	Tricuspid regurgitation grade (0–3)	$1.5 \pm 0.6$	$1.9 \pm 0.6$	< 0.0001
Prosthetic aortic valve7 (1.8%)3 (2.1%)0.261PASP (mmHg)44 ± 1451 ± 14<0.0001	Prosthetic mitral valve	8 (2.1%)	3 (2.1%)	0.874
PASP (mmHg) $44 \pm 14$ $51 \pm 14$ $<0.0001$ RV fractional area change (%) $44 \pm 9$ $30 \pm 10$ $<0.0001$ LV end-distolic volume (mL) $124 \pm 34$ $128 \pm 39$ $0.283$ LV end-systolic volume (mL) $101 \pm 26$ $103 \pm 32$ $0.443$ LVEF (%) $29 \pm 5$ $28 \pm 5$ $0.722$ E/er $20.5 \pm 9.7$ $24.4 \pm 9.5$ $0.0001$ RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV INRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV myocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.322$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn-s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary oedema (%) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Low cardiac output (%) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation severity (0-3) $1.4 \pm 0.5$ $1.4 \pm 0.5$ $0.24 \pm 0.4$ $0.19 \pm 58$ Vena contracta of systolic pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56 \pm 51$ <td>Prosthetic aortic valve</td> <td>7 (1.8%)</td> <td>3 (2.1%)</td> <td>0.261</td>	Prosthetic aortic valve	7 (1.8%)	3 (2.1%)	0.261
RV fractional area change (%) $44 \pm 9$ $30 \pm 10$ <0.0001	PASP (mmHg)	44 ± 14	51 ± 14	< 0.0001
$\begin{array}{llllllllllllllllllllllllllllllllllll$	RV fractional area change (%)	44 ± 9	$30 \pm 10$	< 0.0001
LV end-systolic volume (mL) $101 \pm 26$ $103 \pm 32$ $0.443$ LVEF (%) $29 \pm 5$ $28 \pm 5$ $0.722$ E/ev $20.5 \pm 9.7$ $24.4 \pm 9.5$ $0.004$ RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV IVRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV myocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.332$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn·s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure $295 (75.6\%)$ $131 (91.6\%)$ $<0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ RV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.012$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation velocity (cm/s) <sup>a</sup> $126 \pm 51$ $<0.0001$ $12 \pm 7$ Events $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ HF rehospitalization $122 (31.3\%)$ $31 (21.7\%)$ <td< td=""><td>LV end-diastolic volume (mL)</td><td>124 ± 34</td><td>128 ± 39</td><td>0.283</td></td<>	LV end-diastolic volume (mL)	124 ± 34	128 ± 39	0.283
$\begin{array}{llllllllllllllllllllllllllllllllllll$	LV end-systolic volume (mL)	101 ± 26	$103 \pm 32$	0.443
$E/er$ $20.5 \pm 9.7$ $24.4 \pm 9.5$ $0.004$ RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ $<0.0001$ RV IVRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV myocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.032$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn-s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure $P$ $P$ $295 (75.6\%)$ $131 (91.6\%)$ $<0.001$ Low cardiac output (%) $295 (75.6\%)$ $131 (91.6\%)$ $<0.0001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ Pulmonary oedema (%) $295 (75.6\%)$ $131 (91.6\%)$ $<0.0001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm)^a $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation severity (0-3) $1.4 \pm 0.5$ $1.4 \pm 0.5$ $V$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $12 \pm 7$ Events $12 \pm 7$ $12 \pm 7$ $12 \pm 7$ $12 \pm 7$ Events $12 2 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ CV death $50 (12.8\%)$ $31 (21.7\%)$ <	LVEF (%)	29 ± 5	28 ± 5	0.722
RV IVCT (ms) $78 \pm 16$ $106 \pm 21$ <0.0001	E/e/	$20.5 \pm 9.7$	$24.4 \pm 9.5$	0.004
RV IVRT (ms) $100 \pm 26$ $102 \pm 25$ $0.617$ RV myocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.032$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn:s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ NV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0–3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $0.23 \pm 54$ $<0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $1.4 \pm 0.5$ $12 \pm 7$ </td <td>RV IVCT (ms)</td> <td>78 ± 16</td> <td>106 ± 21</td> <td>&lt; 0.0001</td>	RV IVCT (ms)	78 ± 16	106 ± 21	< 0.0001
RV myocardial performance index $0.73 \pm 0.26$ $0.97 \pm 0.29$ $0.032$ Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn-s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure       Pulmonary oedema (%) $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ RV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary ordema (%) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0–3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation severity (0–3) $1.4 \pm 0.5$ $0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $0.023$ Maximal systolic pulmonary regurgitation (cm) $12 \pm 7$ $0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $12 \pm 7$ $12 \pm 7$ <	RV IVRT (ms)	100 ± 26	102 ± 25	0.617
Tricuspid regurgitation velocity (m/s) $3.0 \pm 0.5$ $3.3 \pm 0.5$ $0.344$ Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failurePulmonary oedema (%) $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ RV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation severity (0-3) $1.4 \pm 0.5$ $<0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $12 \pm 7$ Vena contracta of systolic pulmonary regurgitation velocity (cm/s) $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation (ms) $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation form $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation form $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ Vena to f systolic pulmonary regurgitation $122 (31$	RV myocardial performance index	$0.73 \pm 0.26$	$0.97 \pm 0.29$	0.032
Time-velocity integrity of RVOT (cm) $17.1 \pm 2.6$ $11.6 \pm 3.0$ $<0.0001$ Estimated PVR (dyn s/cm <sup>5</sup> ) $172 \pm 32$ $238 \pm 54$ $<0.0001$ Signs of heart failure $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Pulmonary oedema (%) $295 (75.6\%)$ $121 (84.6\%)$ $<0.0001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ RV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0–3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 51$ $<0.001$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $12 \pm 7$ $<0.001$ Waximal systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ $12 \pm 7$ $<0.0001$ Events $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ CV death $50 (12.8\%)$ $31 (21.7\%)$ $0.003$	Tricuspid regurgitation velocity (m/s)	$3.0 \pm 0.5$	$3.3 \pm 0.5$	0.344
Estimated PVR (dyn-s/cm5) $172 \pm 32$ $238 \pm 54$ <0.0001Signs of heart failurePulmonary oedema (%) $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ <0.0001	Time-velocity integrity of RVOT (cm)	17.1 ± 2.6	$11.6 \pm 3.0$	< 0.0001
Signs of heart failure Pulmonary oedema (%) Low cardiac output (%)295 (75.6%)131 (91.6%)0.001RV failure (%)264 (67.8%)121 (84.6%)<0.0001	Estimated PVR (dyn·s/cm <sup>5</sup> )	172 ± 32	238 ± 54	< 0.0001
Pulmonary oedema (%) Low cardiac output (%) $295 (75.6\%)$ $131 (91.6\%)$ $0.001$ Low cardiac output (%) $264 (67.8\%)$ $121 (84.6\%)$ $<0.0001$ RV failure (%) $102 (26.2\%)$ $112 (78.3\%)$ $<0.0001$ Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0–3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation severity (0–3) $1.4 \pm 0.5$ $<0.0001$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $0.6 \pm 0.2$ Maximal systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ $<0.0001$ Duration of systolic pulmonary regurgitation (ms) $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ CV death $50 (12.8\%)$ $31 (21.7\%)$ $0.003$	Signs of heart failure			
Low cardiac output (%)264 (67.8%)121 (84.6%)<0.0001RV failure (%)102 (26.2%)112 (78.3%)<0.0001	Pulmonary oedema (%)	295 (75.6%)	131 (91.6%)	0.001
RV failure (%)102 (26.2%)112 (78.3%)<0.0001Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ <0.0001	Low cardiac output (%)	264 (67.8%)	121 (84.6%)	< 0.0001
Pulmonary artery diameter (cm) $2.4 \pm 0.4$ $2.5 \pm 0.4$ $0.019$ Pulmonary regurgitation severity (0-3) $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation (cm) <sup>a</sup> $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation velocity (cm/s) <sup>a</sup> $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation severity (0-3) $1.4 \pm 0.5$ $0.6 \pm 0.2$ $0.6 \pm 0.2$ Vena contracta of systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ $122 \pm 7$ Duration of systolic pulmonary regurgitation (ms) $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ CV death $50 (12.8\%)$ $31 (21.7\%)$ $0.003$	RV failure (%)	102 (26.2%)	112 (78.3%)	< 0.0001
Pulmonary regurgitation severity $(0-3)$ $0.4 \pm 0.3$ $0.7 \pm 0.4$ $<0.0001$ Vena contracta of pulmonary regurgitation $(cm)^a$ $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation velocity $(cm/s)^a$ $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation severity $(0-3)$ $1.4 \pm 0.5$ $0.6 \pm 0.2$ $0.023$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ $12 \pm 7$ $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ LeventsHF rehospitalization $122 (31.3\%)$ $86 (60.1\%)$ $<0.0001$ CV death $50 (12.8\%)$ $31 (21.7\%)$ $0.003$	Pulmonary artery diameter (cm)	$2.4 \pm 0.4$	$2.5 \pm 0.4$	0.019
Vena contracta of pulmonary regurgitation (cm)a $0.8 \pm 0.2$ $0.9 \pm 0.2$ $0.023$ Maximal pulmonary regurgitation velocity (cm/s)a $179 \pm 56$ $219 \pm 58$ $<0.0001$ Systolic pulmonary regurgitation severity (0-3) $1.4 \pm 0.5$ $0.6 \pm 0.2$ Vena contracta of systolic pulmonary regurgitation velocity (cm/s) $0.6 \pm 0.2$ $12 \pm 7$ Maximal systolic pulmonary regurgitation (ms) $122$ ( $31.3\%$ ) $86$ ( $60.1\%$ ) $<0.0001$ CV death $50$ ( $12.8\%$ ) $31$ ( $21.7\%$ ) $0.003$	Pulmonary regurgitation severity (0–3)	$0.4 \pm 0.3$	$0.7 \pm 0.4$	< 0.0001
Maximal pulmonary regurgitation velocity (cm/s)a $179 \pm 56$ $219 \pm 58$ <0.0001Systolic pulmonary regurgitation severity (0–3) $1.4 \pm 0.5$ $0.6 \pm 0.2$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 51$ $12 \pm 7$ Maximal systolic pulmonary regurgitation (ms) $122$ (31.3%) $86$ (60.1%)<0.0001	Vena contracta of pulmonary regurgitation (cm) <sup>a</sup>	$0.8 \pm 0.2$	$0.9 \pm 0.2$	0.023
Systolic pulmonary regurgitation severity (0–3) $1.4 \pm 0.5$ Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ Maximal systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ Duration of systolic pulmonary regurgitation (ms) $12 \pm 7$ Events $122 (31.3\%)$ $86 (60.1\%)$ CV death $50 (12.8\%)$ $31 (21.7\%)$	Maximal pulmonary regurgitation velocity (cm/s) <sup>a</sup>	179 ± 56	219 ± 58	< 0.0001
Vena contracta of systolic pulmonary regurgitation (cm) $0.6 \pm 0.2$ Maximal systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ Duration of systolic pulmonary regurgitation (ms) $12 \pm 7$ Events $122 (31.3\%)$ $86 (60.1\%)$ CV death $50 (12.8\%)$ $31 (21.7\%)$	Systolic pulmonary regurgitation severity (0–3)		$1.4 \pm 0.5$	
Maximal systolic pulmonary regurgitation velocity (cm/s) $156 \pm 51$ Duration of systolic pulmonary regurgitation (ms) $12 \pm 7$ Events $122 (31.3\%)$ $86 (60.1\%)$ CV death $50 (12.8\%)$ $31 (21.7\%)$	Vena contracta of systolic pulmonary regurgitation (cm)		$0.6 \pm 0.2$	
Duration of systolic pulmonary regurgitation (ms)         12 ± 7           Events         122 (31.3%)         86 (60.1%)         <0.0001	Maximal systolic pulmonary regurgitation velocity (cm/s)		156 ± 51	
Events HF rehospitalization122 (31.3%)86 (60.1%)<0.0001CV death50 (12.8%)31 (21.7%)0.003	Duration of systolic pulmonary regurgitation (ms)		12 ± 7	
HF rehospitalization         122 (31.3%)         86 (60.1%)         <0.0001           CV death         50 (12.8%)         31 (21.7%)         0.003	Events			
CV death         50 (12.8%)         31 (21.7%)         0.003	HF rehospitalization	122 (31.3%)	86 (60.1%)	< 0.0001
	CV death	50 (12.8%)	31 (21.7%)	0.003
All cardiovascular events (HF and CV death)         139 (35.8%)         98 (68.5%)         <0.0001	All cardiovascular events (HF and CV death)	139 (35.8%)	98 (68.5%)	< 0.0001

Table 1 Clinical characteristics and echocardiographic parameters according to the presence of systolic PR or no systolic PR

BP, blood pressure; CV, cardiovascular; E/e<sup>7</sup>, peak early diastolic mitral flow velocity divided by peak early diastolic mitral annular velocity; HF, heart failure; IVCT, isovolumic contraction time; IVRT, isovolumic relaxation time; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA FC, functional classification according to the New York Heart Association; PASP, pulmonary artery systolic pressure; PR, pulmonary regurgitation; PVR, pulmonary vascular resistance; RV, right ventricular; RVOT, right ventricular outflow tract. <sup>a</sup>Number of no systolic PR = 204 and number of systolic PR = 143.

# Results

#### Prevalence of systolic pulmonary regurgitation

Totally, 533 cases first hospitalized for systolic HF and LVEF < 35% were enrolled. Echocardiographies were available at each case, and subsequent echocardiographic studies after indexed hospitalization were under analyses. The clinical characteristics and echocardiographic parameters were listed in *Table 1*. Of 533 HF cases, 143 (26.8%) had systolic PR with variable severity grade during indexed hospitalization. There were 85 with Grade 1 of systolic PR, 55 with Grade 2, and 3 with Grade 3. Almost all systolic PR disappeared after discharge, and only 14% (20/143) cases demonstrated systolic PR during late follow-up.

Consequentially screening 5480 cases with normal LVEF from E-Da echocardiographic database in 1 year (*Table 2*), we found that only 18 cases had systolic PR and the prevalence was 0.3%. The identifiable/possible causes and echocardiographic parameters were shown in *Table 2*.

 Table 2
 Clinical characteristics and echocardiographic parameters

 of patients with normal LV systolic function and systolic PR

Variables	Systolic PR N = 18
Age (years)	72 ± 12
Systolic BP (mmHg)	125 ± 28
Heart rate (b.p.m.)	76 ± 16
Male gender (%)	10 (55.6%)
Hypertension (%)	5 (27.8%)
Diabetes (%)	4 (22.2%)
Coronary artery disease (%)	2 (11.1%)
Atrial fibrillation (%)	6 (33.3%)
Bundle branch block (%)	1 (5.6%)
Renal dysfunction (%)	3 (16.7%)
Mitral stenosis more than moderate degree (%)	3 (16.7%)
Mitral regurgitation grade (0–3)	$1.5 \pm 0.6$
Aortic stenosis more than moderate degree (%)	0 (0%)
Aortic regurgitation grade (0–3)	$1.2 \pm 0.8$
Tricuspid regurgitation grade (0–3)	$1.7 \pm 0.9$
Mitral annuloplasty (%)	1 (5.6%)
Prosthetic mitral valve and aortic valve (%)	1 (5.6%)
RV failure (%)	11 (61.1%)
PASP (mmHg)	45 ± 12
RV fractional area change (%)	35 ± 8
LV end-diastolic volume (mL)	64 ± 12
LV end-systolic volume (mL)	32 ± 7
LVEF (%)	55 ± 6
E/e/	$14.3 \pm 6.4$
Pulmonary artery diameter (cm)	$2.3 \pm 0.3$
Pulmonary regurgitation severity (0–3)	$0.7 \pm 0.6$
Vena contracta of pulmonary regurgitation (cm)	$0.8 \pm 0.2$
Maximal pulmonary regurgitation velocity (cm/s)	181 ± 41
Systolic pulmonary regurgitation severity (Grades 0–3)	$1.3 \pm 0.6$
Vena contracta of systolic pulmonary regurgitation (cm)	$0.6 \pm 0.2$
Maximal systolic pulmonary	128 ± 33
regurgitation velocity (cm/s)	
Duration of systolic pulmonary regurgitation (ms)	11 ± 3

Abbreviations as shown in *Table 1*. Totally, 5480 cases with normal left ventricular systolic function were screened.

## Systolic pulmonary regurgitation relates to other echocardiographic parameters

Compared with cases without systolic PR, systolic PR group had higher pulmonary artery systolic pressure, higher E/e/, and lower RV fractional area change. Pulsed-wave TDI showed longer RV IVCT and higher myocardial performance index in the systolic PR group than those without systolic PR (106  $\pm$  21 vs. 78  $\pm$  16 ms, P < 0.0001 and 0.93  $\pm$  0.29 vs.  $0.73 \pm 0.26$ , P = 0.032, respectively). Estimated PVRs were higher in the systolic PR group than those without systolic PR (238  $\pm$  54 vs. 172  $\pm$  32 dyn·s/cm<sup>5</sup>; P < 0.0001). Patients with systolic PR showed larger pulmonary artery diameter, more severe PR, and higher maximal PR velocity (219 ± 58 vs. 179 ± 56, P < 0.0001). Multivariate logistic regression analyses revealed that systolic PR correlated to baseline PR, E/e/, RV fractional area change, estimated PVR, low cardiac output, and pulmonary oedema at enrolment (Table 3).

#### **Outcome analyses**

Outcome analyses were according to time to event, and the mean duration from first indexed hospitalization for HF to the end of study was  $5.9 \pm 4.0$  years. Kaplan–Meier curves of cardiovascular events according to systolic PR were shown in *Figure 2A–2C*. Systolic PR was associated significantly with cardiovascular events, particularly HF rehospitalization (logrank P < 0.0001). Regarding cardiovascular death, it also reached statistical significance (log-rank P = 0.0091). Cardiovascular events according to the grade of systolic PR were shown in *Figure 3*.

To predict cardiovascular events, age, systolic PR, pulmonary artery systolic pressure, RV dysfunction at enrolment, E/e<sup>*i*</sup>, and mitral and tricuspid regurgitation severity were associated with events in univariate analyses (*Table 4*). Multivariate analyses revealed that both age and systolic PR were associated independently with further cardiovascular events. The presence of systolic PR had 2.266-fold risk increase of further HF hospitalization and cardiovascular death (hazard ratio 2.266, 95% confidence interval 1.682–3.089, P < 0.0001).

#### Invasive haemodynamic measurements

*Figure 4* shows invasive haemodynamic measurements in a case with systolic PR at Day 7 of indexed HF hospitalization. Simultaneous pressure wave recordings show that LV systolic response occurred earlier than pulmonary artery (*Figure 4A*), and aortic systolic response occurs earlier than pulmonary artery (*Figure 4B*). Ineffective contraction of the right ventricle at second sinus beat suggested RV dysfunction, and

Variables	Odds ratio (95% CI)	P values
Age (years)	1.009 (0.989–1.028) per 1 year increase	0.39
Atrial fibrillation	0.719 (0.386–1.362)	0.312
Pulmonary artery diameter (cm)	1.098 (0.531–2.269) per 1 cm increase	0.801
Pulmonary regurgitation severity (0–3)	2.489 (1.334–4.641) per 1 grade increase	0.004
Pulmonary artery systolic pressure (mmHg)	1.012 (0.990–1.035) per 1 mmHg increase	0.295
Tricuspid regurgitation severity (0–3)	0.899 (0.335–2.417) per 1 grade increase	0.834
Bundle branch block (LBBB or RBBB)	1.582 (0.644–3.886)	0.317
Left ventricular ejection fraction (%)	1.045 (0.979–1.116) per 1% increase	0.185
Right ventricular fractional area change (%)	0.938 (0.900–0.979) per 1% increase	0.003
Estimated PVR (dyn·s/cm <sup>5</sup> )	1.424 (1.244–1.630) per 10 dyn s/cm <sup>5</sup> increase	< 0.0001
Low cardiac output at enrolment	1.178 (1.036–2.572)	0.006
Pulmonary oedema at enrolment	2.704 (1.422-5.131)	< 0.0001
E/e/	1.072 (1.012–1.145) per 1 unit increase	0.011

Table 3 Multivariate logistic regression analyses of the relationship between systolic pulmonary regurgitation and clinical characteristics in heart failure

CI, confidence interval; LBBB, left bundle branch block; PVR, pulmonary vascular resistance; RBBB, right bundle branch block.

Figure 2 Kaplan–Meier curves of cardiovascular events according to the presence of systolic pulmonary regurgitation (PR). Plots of (A) heart failure rehospitalization, (B) cardiovascular death, and (C) all cardiovascular events.







simultaneous pressure waves of right heart system revealed that pulmonary artery pressure was higher than RV pressure at early systolic phase (*Figure 4C*). Therefore, systolic PR existed at this period.

## Discussion

## High incidence of systolic pulmonary regurgitation and clues

The phenomenon of systolic PR was not uncommon at first hospitalization for systolic LV HF (26.8%, 143/533), associated significantly with further cardiovascular outcome (*Table 1*), and disappeared after discharge. Only 14% (20/143) cases persisted in systolic PR during late follow-up in this retrospective study. It was very rare in normal LVEF (0.3%, 18/5480) (*Table 2*). Like systolic AR, physicians are acquired to focus more on systolic PR.<sup>1–7</sup> Before elucidating systolic PR, systolic AR might provide some clues. Based on data, the prevalence of systolic AR is higher in HF population (5.9% vs. 2.1%).<sup>18,19</sup> Transient systolic AR can be an ineffective ejection phenomenon, which is commonly associated with ventricular extrasystole and the use of LV assist devices in patients, being a consequence of artificial suction by the device from the LV apex rather than a spontaneous finding, in HF patients with

pre-existing AR.<sup>7</sup> Ineffective ejection responsible for generating pulsus alternans in HF cases could be explained by contractility variation as myocardial intracellular calcium availability during excitation–contraction coupling. It is also possible to observe sustained systolic AR in HF cases with sinus rhythm wherein rate of development of LV pressure is very slow and the aortic systolic pressure exceeds the LV systolic pressure during prolonged IVCT.<sup>19</sup>

Invasive haemodynamic recordings (*Figure 4*) demonstrated that systolic PR was due to the delay of RV systolic response with prolonged RV IVCT, and reverse pressure gap between pulmonary artery and the right ventricle after QRS of ECG. Ineffective RV ejection at sinus rhythm (*Figure 4C*) also provided the clues. Transient elevation of pulmonary artery pressure above RV pressure can be also due to a decrease in pulmonary artery compliance and an increase in main pulmonary artery size, impedance, and transmission time of the velocity wave.

## Biventricular pumping dysfunction, high pulmonary vascular resistance, and pre-existing pulmonary regurgitation as determinants

Severe left-side HF with low cardiac output and pulmonary oedema indicates pumping failure with congestive left

VariablesHazard ratio (95% Cl) $P$ valuesAge (years)Age (years)0.0141.010 (0.773-1.320)0.043Age (years)1.011 (1.002-1.019) per 1 year increase0.0141.010 (0.773-1.320)Diabetes1.001 (0.773-1.320)0.9431.010 (0.773-1.320)Diabetes1.010 (0.773-1.320)0.09431.010 (0.773-1.320)Diabetes1.010 (0.773-1.320)0.03250.187Atrial fibrillation1.187 (0.920-1.625)0.0900.752Atrial fibrillation1.135 (0.862-1.662)0.7520.756Coronary artery disease1.135 (0.862-1.662)0.7062.266 (Systolic pulmonary regurgitation grade (0-3)1.005 (0.978-1.034) per 1 % increase0.7062.266 (Nitral regurgitation grade (0-3)1.190 (0.940-1.507) per 1 grade increase0.0221.033 (Minonary regurgitation grade (0-3)1.256 (1.028-1.488) per 1 grade increase0.0250.995 (Pulmonary redem a sterrolment1.286 (0.954-1.509) per 1 mmHg increase0.0250.995 (Pulmonary ordem a sterrolment1.286 (0.954-1.956)0.0221.001 (Pulmonary ordem a sterrolment1.286 (0.954-1.956)0.0301.001 (Pulmonary ordem a tenrolment1.808 (1.400-2.334)<0.00011.223 (	e analysis	Multivariate analysis	
Age (years)       1.011 (1.002-1.019) per 1 year increase       0.014       1.010 (         Gender (female)       1.010 (0.773-1.320)       0.825       0.943       1.010 (         Diabetes       1.010 (0.773-1.320)       0.825       0.943       1.010 (         Hypertension       1.032 (0.783-1.359)       0.825       0.825       0.187       0.943         Hypertension       1.187 (0.920-1.532)       0.090       0.187       0.090       0.187         Atrial fibrillation       1.135 (0.955-1.625)       0.965-1.625)       0.090       0.752       0.766         Coronary artery disease       1.135 (0.952-1.625)       0.862-1.662)       0.776       0.706       2.266 (         Systolic pulmonary regurgitation       1.135 (0.920-1.534) per 1 % increase       0.776       0.776       0.706       2.266 (         Systolic pulmonary regurgitation grade (0-3)       1.190 (0.940-1.507) per 1 grade increase       0.148       1.033 (         Pulmonary regurgitation grade (0-3)       1.198 (1.027-1.399) per 1 grade increase       0.025       0.995 (         Pulmonary regurgitation grade (0-3)       1.198 (1.027-1.399) per 1 mmHg increase       0.025       0.995 (         Pulmonary regurgitation grade (0-3)       1.198 (1.027-1.399) per 1 mmHg increase       0.0148       1.001 (      <	cl) P values	Hazard ratio (95% Cl)	P values
Gender (female)       1.010 (0.773-1.320)       0.943         Diabetes       1.010 (0.773-1.320)       0.943         Diabetes       1.032 (0.783-1.359)       0.825         Hypertension       1.032 (0.773-1.320)       0.825         Atrial fibrillation       1.187 (0.920-1.532)       0.825         Atrial fibrillation       1.135 (0.920-1.532)       0.090         Coronary artery disease       1.135 (0.965-1.652)       0.090         Systolic pulmonary regurgitation fraction (%)       1.135 (0.978-1.034) per 1% increase       0.776         Systolic pulmonary regurgitation grade (0-3)       1.190 (0.940-1.507) per 1 grade increase       0.0148       1.033 (         Nitral regurgitation grade (0-3)       1.198 (1.027-1.389) per 1 grade increase       0.0122       1.033 (         Pulmonary regurgitation grade (0-3)       1.198 (1.027-1.389) per 1 grade increase       0.025       0.995 (         Pulmonary artery systolic pressure (mmHg)       1.010 (1.001-1.029) per 1 mmHg increase       0.025       0.995 (         Pulmonary artery systolic pressure (mmHg)       1.286 (0.954-1.956)       0.089       0.030       1.001 (0         Pulmonary regurgitation grade (0-3)       1.010 (1.001-1.029) per 1 mmHg increase       0.030       1.001 (0         Pulmonary artery systolic pressure (mmHg)       1.286 (0.954-1.956)	r increase 0.014	1.010 (1.001–1.018) per 1 year increase	0.027
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	0.943	-	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	0.825		
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	0.187		
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	060.0		
Left ventricular ejection fraction (%)         1.005 (0.978–1.034) per 1% increase         0.706           Systolic pulmonary regurgitation         2.598 (2.003–3.369)         < 0.0001	0.752		
Systolic pulmonary regurgitation         2.598 (2.003–3.369)         <0.0001         2.266 (           Pulmonary regurgitation grade (0–3)         1.190 (0.940–1.507) per 1 grade increase         0.148         1.033 (           Mitral regurgitation grade (0–3)         1.198 (1.027–1.398) per 1 grade increase         0.022         1.033 (           Mitral regurgitation grade (0–3)         1.198 (1.027–1.398) per 1 grade increase         0.022         1.033 (           Mitral regurgitation grade (0–3)         1.236 (1.028–1.488) per 1 grade increase         0.025         0.995 (           Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (           Pulmonary oedema at enrolment         1.286 (0.954–1.956)         0.185         0.089         1.223 (           Right heart failure at enrolment         1.808 (1.400–2.334)         0.0001         1.223 (	ncrease 0.706		
Pulmonary regurgitation grade (0–3)         1.190 (0.940–1.507) per 1 grade increase         0.148           Mitral regurgitation grade (0–3)         1.198 (1.027–1.398) per 1 grade increase         0.022         1.033 (1.033 (1.034)           Mitral regurgitation grade (0–3)         1.198 (1.028–1.488) per 1 grade increase         0.025         0.995 (1.035 (1.034)           Tricuspid regurgitation grade (0–3)         1.236 (1.028–1.488) per 1 grade increase         0.025         0.995 (1.036)           Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (1.001           Pulmonary oedema at enrolment         1.286 (0.886–1.866)         0.185         0.089         1.001 (1.001–1.022) per 1 mmHg increase         0.089           Right heart failure at enrolment         1.808 (1.400–2.334)         1.808         0.284–1.956)         0.089         1.223 (1.223 (1.223 (1.202))	<0.0001	2.266 (1.682–3.089)	<0.0001
Mitral regurgitation grade (0–3)         1.198 (1.027–1.398) per 1 grade increase         0.022         1.033 (1.033 (1.025)           Tricuspid regurgitation grade (0–3)         1.236 (1.028–1.488) per 1 grade increase         0.025         0.995 (1.036)           Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (1.001 (1.001–1.029) per 1 mmHg increase           Pulmonary oedema at enrolment         1.286 (0.886–1.866)         0.185         0.089           Low cardiac output at enrolment         1.386 (0.954–1.956)         0.089         1.223 (1.223 (1.223 (1.202))	de increase 0.148		
Tricuspid regurgitation grade (0–3)         1.236 (1.028–1.488) per 1 grade increase         0.025         0.995 (i           Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (i           Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (i           Pulmonary oedema at enrolment         1.286 (0.886–1.866)         1.286 (0.954–1.956)         0.185         0.089           Low cardiac output at enrolment         1.386 (0.954–1.956)         0.389         1.223 (i         0.0001         1.223 (i	de increase 0.022	1.033 (0.856–1.247) per 1 grade increase	0.734
Pulmonary artery systolic pressure (mmHg)         1.010 (1.001–1.029) per 1 mmHg increase         0.030         1.001 (1           Pulmonary oedema at enrolment         1.286 (0.886–1.866)         0.185         0.185           Low cardiac output at enrolment         1.386 (0.954–1.956)         0.089         0.089           Right heart failure at enrolment         1.808 (1.400–2.334)         <0.0001	de increase 0.025	0.995 (0.772–1.281) per 1 grade increase	0.967
Pulmonary oedema at enrolment 1.286 (0.886–1.866) 0.185 Low cardiac output at enrolment 1.386 (0.954–1.956) 0.089 Right heart failure at enrolment 1.808 (1.400–2.334) <0.0001 1.223 (	nHg increase 0.030	1.001 (0.989–1.012) per 1 mmHg increase	0.918
Low cardiac output at enrolment         1.386 (0.954–1.956)         0.089           Right heart failure at enrolment         1.808 (1.400–2.334)         <0.0001	0.185	•	
Right heart failure at enrolment         1.808 (1.400–2.334)         <0.0001         1.223 (1.400–2.334)	0.089		
	<0.0001	1.223 (0.898–1.664)	0.201
E/e/ at enrolment 0.023 1.113 (1.012–1.334) per 1 unit increase 0.023 1.014 (i	t increase 0.023	1.014 (0.982–1.298) per 1 unit increase	0.096

ventricle, which brings high LV filling pressure. The pressure might go backward to left atrium and pulmonary circulation, which induces high PVR. All cases with systolic PR already had PR at baseline. If the right ventricle did not function well (RV fractional area change and RV myocardial performance index in Table 1), RV output might decrease markedly after facing very high PVR. Therefore, the existence of systolic PR indicated (i) RV pumping dysfunction, (ii) high PVR, and (iii) pre-existing PR. In late follow-up echocardiographies, 14% (20/143) showed persistent systolic PR, the grade of systolic PR less than that in indexed hospitalization. We assumed that the reduction of LV filling pressure improved PVR and RV function, which causes the disappearance of systolic PR in follow-up period. The prevalence of atrial fibrillation and bundle branch block was similar at patients with and without systolic PR (Tables 1 and 3), which indicated that systolic PR was not induced by arrhythmia or bundle branch block. However, advanced tissue Doppler imaging and two-dimensional/ three-dimensional speckle tracking imaging for all segments of both right and left ventricles were not performed in the current study. The impacts of mechanical dyssynchrony (interventricular or intraventricular) on systolic PR require further investigation.<sup>20–22</sup> In addition, early wave reflection may increase RV wall stress and compromise RV function. It deserves to explore whether it contributes in some physiology variants to systolic PR or not. Further study design uses invasive pressure-volume conductance catheter technique to assess magnitude and timing of the reflected pressure, and analyses its correlation with RV function,<sup>22,23</sup> in patients with or without systolic PR.

## **Clinical implications**

For clinical application, physicians need to pay more attention to systolic LV HF cases with systolic PR and focus on the need of rapid reduction of high PVR, caused by poor LV compliance, high LV filling pressure, and mitral regurgitation. Loop diuretic is not a good choice because biventricular HF with profound low cardiac output already exists. Although loop diuretic reduces LV filling pressure and improves pulmonary oedema dramatically, it can be complicated with lower cardiac output and multiple organ failure. In this kind of biventricular HF cases, rapid up-titration of vasodilator after adequate preload with promotion forward flow and the reduction of LV filling pressure is a better choice.<sup>24</sup> In the meantime, physicians should keep maximal tolerable doses of evidence-based medications and consider device therapy as second line if medical treatment fails.

#### **Study limitations**

We acknowledge certain limitations of this study. This investigation was a single-centre retrospective observational **Figure 4** Invasive haemodynamic measurements in a case with systolic pulmonary regurgitation (PR). (A) Simultaneous pressure wave recording of the left ventricle (LV) and pulmonary artery (PA). (B) Simultaneous pressure wave recording of aorta (Ao) and PA. (C) Ineffective contraction of RV at second sinus beat indicates poor right ventricular performance, otherwise simultaneous pressure wave recording of RV and PA; due to delayed systolic response of RV, PA pressure was higher than RV at early systolic phase, which brought systolic pulmonary regurgitation.



study, a need for prospective validation. There were several questions needed to solve. For example, mechanical delay of the right ventricle for overcoming high PVR caused systolic PR, but it could not explain why tricuspid regurgitation and systolic PR occurred at the same time. We assume that the rate of increase of early systolic RV pressure might be delayed, so the ejection proceeds with RV systolic pressure exceeding right atrial pressure but is delayed to exceed (expectedly higher) diastolic pulmonary artery pressure. Second, the onset/end time of systolic PR compared with QRS termination of single-lead ECG was sometimes very hard to identify if artefact or arrhythmia occurred during echocardiography. Thus, we only enrolled well-documented pulmonary artery backward flow after clear image of QRS of ECG in multiple beats. Third, RV dysfunction was just dependent on RV fractional area change <35%. The geometry of the right ventricle is not similar to that of the left ventricle, and the function of the right ventricle assessed by area change at apical four-chamber view might not be accurate enough to diagnose RV failure. It is also necessary to improve RV function assessment in further study. Otherwise, diuretic use during acute systolic HF might omit RV failure sign. Thus, only 78.3% patients of systolic PR group could find RV failure sign, although RV fractional area change in systolic PR group was much lower than that in the group without systolic PR. Fourth, high E/e/ and PVR in systolic HF with systolic PR indicate that the primary driver of this phenomenon is LV diastolic dysfunction and high LV filling pressure. In patients with normal LVEF, the underlying cause of systolic PR could not be identified, although some cases had valvular heart disease, RV dysfunction, or elevated E/e/. It requires more integrated studies, including multimodality images and invasive haemodynamic measurement. Thus, we cannot conclude the primary driver of systolic PR until further prospective studies provide more data.

# Conclusion

Systolic PR is common in first hospitalization of systolic LV HF and is associated with high PVR and RV dysfunction. It

can subside after treatment. In spite of short-term phenomenon, systolic PR indicating acute biventricular HF has a significant impact on long-term cardiovascular outcome.

# **Conflict of interest**

None declared.

# Funding

This work was supported by the Ministry of Science and Technology, Taiwan (MOST 109-2314-B-650-014 and 106-2314-B-038-094) and E-Da Hospital (EDAHP106026 and EDAHP105027).

# References

- Mohan JC, Mohan V, Shukla M, Sethi A. Systolic aortic regurgitation in rheumatic carditis: mechanistic insight by doppler echocardiography. *Indian Heart* J 2018; **70**: 272–277.
- Saura D, López-Cuenca A, Oliva MJ, Caballero L, González-Carrillo J, Espinosa MD, López-Ruiz M, García-Navarro M, de la Morena G. Accuracy of systolic aortic regurgitation in the diagnosis of heart failure: a predictive approach. *Int J Clin Pract* 2015; 69: 485–490.
- Bonaque JC, Sánchez-Espino AD, Merchán G, González-Juanatey JR. Systolic aortic regurgitation. a new prognostic marker in heart failure patients? *Rev Esp Cardiol* 2015; 68: 160–162.
- Kronzon I, Konecky N, Tunick PA. Systolic aortic regurgitation: a hemodynamic challenge for the clinician. J Am Soc Echocardiogr 1995; 8: 941–943.
- Saura D, Oliva MJ, Peñafiel P, de la Morena G, Valdés M. Systolic aortic regurgitation: a not-so-rare phenomenon. *Int J Cardiol* 2010; 145: 291–292.
- Saura D, González J, de la Morena G, Valdés-Chávarri M. Systolic aortic regurgitation. *Eur J Echocardiogr* 2008; 9: 284–285.
- Ramos GG, Bulnes MJ, Paredes CA, Gabrielli NL. Phantom systole: a failed ejection phenomenon between pulsus alternans and systolic aortic regurgitation. *CASE (Phila)* 2020; 4: 477–481.

- Honda Y, Nagai T, Sugano Y, Honda S, Okada A, Asaumi Y, Aiba T, Noguchi T, Kusano K, Ogawa H, Yasuda S, Anzai T, NaDEF investigators. Impact of elevated end-diastolic pulmonary regurgitation gradient on worse clinical outcome in hospitalized patients with heart failure. *Am J Cardiol* 2017; **119**: 604–610.
- American Diabetes Association. Classification and diagnosis of diabetes. In: 2016 Standards of Medical Care in Diabetes. *Diab Care* 2016; **39**: S13–S22.
- Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681–689.
- Ommen SR, Nishimura RA, Hurrell DG, Klarich KW. Assessment of right atrial pressure with 2-dimentional and doppler echocardiography: a simultaneous catheterization and echocardiographic study. *Mayo Clin Proc* 2000; **75**: 24–29.
- Rivas-Gotz C, Manolios M, Thohan V, Nagueh SF. Impact of left ventricular ejection fraction on estimation of left ventricular filling pressure using tissue doppler and flow propagation velocity. *Am J Cardiol* 2003; **91**: 780–784.
- Hsiao SH, Lee CY, Chang SM, Yang SH, Lin SK, Huang WC. Pulmonary embolism and right heart function: insights from myocardial doppler tissue imaging.

J Am Soc Echocardiogr 2006; **19**: 822–828.

- Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41: 1021–1027.
- Markush D, Ross RD, Thomas R, Aggarwal S. Noninvasive echocardiographic measures of pulmonary vascular resistance in children and young adults with cardiomyopathy. J Am Soc Echocardiogr 2018; 31: 807–815.
- Abbas AE, Franey LM, Marwick T, Maeder MT, Kaye DM, Vlahos AP, Serra W, Al-Azizi K, Schiller NB, Lester SJ. Noninvasive assessment of pulmonary vascular resistance by doppler echocardiography. J Am Soc Echocardiogr 2013; 26: 1170–1177.
- 17. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017; 30: 303–371.
- Unger P, Vanderbossche IL. Doppler demonstration of systolic aortic regurgitation. Am Heart J 1992; 123: 805–807.

- 19. Saura D, Peñafiel P, Martínez J, de la Morena G, García-Alberola A, Soria F, Garrido IP, Valdés M. The frequency of systolic aortic regurgitation regurgitation and its relationship to heart failure in a consecutive series of patients. *Rev Esp Cardiol* 2008; **61**: 771–774.
- Ghio S, Constantin C, Klersy C, Serio A, Fontana A, Campana C, Tavazzi L. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS

duration. *Eur Heart J* 2004; **25**: 571–578.

- 21. Roberto BR. The overloaded right heart and ventricular interdependence. *Cardiovasc Res* 2017; **113**: 1474–1485.
- 22. Roberto BR. The overloaded right heart and ventricular interdependence. *Cardiovasc Res* 2017; **113**: 1474–1485.
- Fukumitsu M, Westerhof BE, Ruigrok D, Braams NJ, Groeneveldt JA, Ahmed A, Bayoumy AA, Marcus JT, Meijboom LJ, de Man FS, Westerhof N, Bogaard HJ,

Noordegraaf AV. Early return of reflected waves increases right ventricular wall stress in chronic thromboembolic pulmonary hypertension. *Am J Physiol Heart Circ Physiol* 2020; **319**: H1438–H1450.

 Hsiao SH, Lin SK, Chiou YR, Cheng CC, Hwang HR, Chiou KR. Utility of left atrial expansion index and stroke volume in management of chronic systolic heart failure. J Am Soc Echocardiogr 2018; 31: 650–659.